Cristiana Balocchi

Title: Inventor Cristiana Balocchi and Her Contributions to Vaccine Development

Introduction

Cristiana Balocchi, an accomplished inventor based in Siena, Italy, has made significant strides in the field of immunology through her innovative research and development efforts. With a focus on meningococcal vaccines, her expertise has led to the creation of a patent that enhances the assessment of vaccine potency and immunogenicity.

Latest Patents

Cristiana holds a patent titled "Bactericidal antibody assays to assess immunogenicity and potency of meningococcal capsular saccharide vaccines." This patent describes a range of compositions, methods, and kits designed specifically for evaluating the immunogenicity and effectiveness of meningococcal capsular saccharide vaccines. The innovative approach involves measuring the binding of bactericidal antibodies to components of the vaccine, ensuring its efficacy in providing protection against infections.

Career Highlights

Cristiana Balocchi has established a commendable career at Novartis AG, a leading pharmaceutical company known for its commitment to research and development in healthcare. Her contributions are instrumental in advancing vaccine technology, specifically focusing on meningococcal infections that pose significant health risks. Balocchi’s dedication to scientific excellence has positioned her as a leader in her field.

Collaborations

In her professional journey, Cristiana collaborates with talented coworkers, including Enrico Luzzi and Marilena Paludi. Together, they contribute to ongoing projects aimed at improving vaccine assessments and overall public health outcomes. These collaborations reflect her ability to work effectively within a team, bringing diverse perspectives together to achieve common goals in the field of immunology.

Conclusion

Cristiana Balocchi’s innovative spirit and dedication to vaccine research exemplify the vital role that inventors play in advancing medical science. Her patent on bactericidal antibody assays represents a significant contribution to the assessment of meningococcal capsular saccharide vaccines. Through her work at Novartis AG and collaborations with esteemed colleagues, Balocchi continues to pave the way for advancements that enhance global health and safety.